Mark Stenhouse
Director/Board Member chez PHATHOM PHARMACEUTICALS, INC.
Fortune : 95 580 $ au 31/03/2024
Profil
Mark Stenhouse is an Independent Director at Phathom Pharmaceuticals, Inc. He previously worked as a Director at Prometheus Laboratories, Inc. from 2018 to 2020.
Mark also served as the Vice President-US Immunology at Abbott Laboratories from 2006 to 2010 and as the General Manager-Screening at EXACT Sciences Corp.
from 2019 to 2021.
Prior to that, he held the position of Vice President-U.S.
Immunology at AbbVie, Inc. from 2016 to 2018.
Mark's current job includes being the Chief Operating Officer at Prometheus Biosciences, Inc. from 2021 to 2023.
He completed his undergraduate degree at the College of Charleston.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 25/05/2023 | 9 000 ( 0,02% ) | 95 580 $ | 31/03/2024 |
Postes actifs de Mark Stenhouse
| Sociétés | Poste | Début |
|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Director/Board Member | 17/03/2020 |
Anciens postes connus de Mark Stenhouse
| Sociétés | Poste | Fin |
|---|---|---|
| PROMETHEUS BIOSCIENCES, INC. | Chief Operating Officer | 16/06/2023 |
| EXACT SCIENCES CORPORATION | Corporate Officer/Principal | 01/01/2021 |
Prometheus Laboratories, Inc.
 Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA. | Director/Board Member | 01/10/2020 |
| ABBVIE INC. | Corporate Officer/Principal | 01/03/2018 |
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01/03/2010 |
Formation de Mark Stenhouse
| College of Charleston | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| EXACT SCIENCES CORPORATION | Health Technology |
| ABBVIE INC. | Health Technology |
| PHATHOM PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Prometheus Laboratories, Inc.
Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA. | Health Technology |
Prometheus Biosciences, Inc.
 Prometheus Biosciences, Inc. BiotechnologyHealth Technology Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases. The company was founded by Scott Glenn and Stephan Targan on October 26, 2016 and is headquartered in San Diego, CA . | Health Technology |
